| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCE-016 | Chenodeoxycholic acid | >98%,Standard References |
|
| DC11547 | LY-2562175 Featured | LY2562175 is a potent and selective FXR agonist, with an EC50 of 193 nM. |
|
| DC10868 | Cilofexor Featured | Cilofexor (GS-9674, GS9674) is novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models. |
|
| DC8069 | Fexaramate Featured | Fexaramate is a potent, selective farnesoid X receptor agonist. |
|
| DC8085 | Fexaramine Featured | Fexaramine is a potent, selective FXR activator. |
|
| DC8070 | Fexarene Featured | Fexarene is a potent, selective farnesoid X receptor agonist. |
|
| DC8071 | Fexarine Featured | Fexarine is a potent, selective farnesoid X receptor agonist. |
|
| DC7566 | GW-4064 Featured | GW 4064 is a selective, non-steroidal farnesoid X receptor (FXR) agonist (EC50 = 15 nM). |
|
| DC7430 | Obeticholic acid (INT-747) Featured | INT-747(Obeticholic acid; 6-ECDCA) is a potent and selective FXR agonist(EC50=99 nM) endowed with anticholestatic activity. |
|
| DC10470 | SB756050 Featured | SB-756050 is a Farnesoid X receptor (FXR) (NR1H4) agonist. |
|
| DC10737 | Tropifexor (LJN452) Featured | Tropifexor (LJN452) is a highly potent non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). |
|
| DC7040 | WAY-362450 (XL335; Turofexorate isopropyl) Featured | WAY-362450 (XL335; Turofexorate isopropyl) is a highly potent, selective, and orally active farnesoid X receptor (FXR) agonist with an EC50 of 4 nM.WAY-362450 is useful for dyslipidemia. |
|
| DC28475 | NR1H4 activator 1 | NR1H4 activator 1 is a potent and selective Famesoid X Receptor (FXR) agonist, extracted from patent WO2018152171A1, example 4. NR1H4 activator 1 shows strong FXR agonistic potency with a EC50 value of 1 nM in a Human FXR (NR1H4) Assay. NR1H4 activator 1 has the potential for treatment of gastrointestinal disease. |
|
| DC28850 | Tauro-Obeticholic acid | Tauro-Obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist. |
|
| DC28851 | Glyco-Obeticholic acid | Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist. |
|
| DC46688 | Sevelamer-(d5)n hydrochloride | Sevelamer-(d5)n hydrochloride is the deuterium labeled Sevelamer hydrochloride. Sevelamer hydrochloride is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin. |
|
| DC47987 | FXR/TGR5 agonist 1 | FXR/TGR5 agonist 1 has agonist action on FXR and TGR5, and can be used for the treatment of fatty liver disease. |
|
| DC50221 | NDB | NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research. |
|
| DC50222 | BMS-986318 | BMS-986318 is a potent nonbile acid FXR agonist with EC50s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis. |
|
| DC50223 | Chenodeoxycholic acid-d5 | Chenodeoxycholic acid-d5 (CDCA-d5) is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. |
|
| DC50224 | Chenodeoxycholic acid-13C | Chenodeoxycholic acid-13C (CDCA-13C) is the 13C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. |
|
| DC70074 | GSK-2324 | GSK-2324 (GSK2324) is a potent, selective, full FXR agonist with EC50 of 120 nM in FRET assay. |
|
| DC71956 | BMS-986339 Featured | BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. |
|
| DC71957 | Omesdafexor | Omesdafexor is a FXR agonist. Omesdafexor can be used in the research of liver disease or a metabolic inflammation-mediated disease. |
|
| DC73829 | HPG1860 | HPG1860 is a potent, selective, nonbile acid full FXR agonist with EC50 of 5 nM and 18 nM in FR-FRET and luciferase assays, respectively. |
|
| DC73830 | ID166 | ID119031166 (ID166) is a novel potent, selective FXR agonist with EC50 of 3 nM and 5 nM in TR-FRET FXR co-activator assay and FXR reporter assay, respectively. |
|
| DC73831 | MET409 | MET409 (MET-409) is a potent, selective farnesoid X receptor (FXR) agonist with EC50 of 16 nM (human FXR). |
|
| DC73832 | PDL103 | PDL103 is a potent, dual FXR/GPBAR1 antagonist with IC50 of 10 and 19 uM, respectively. |
|
